Parkinson's disease dementia: Clinical correlates of brain SPECT perfusion and treatment

Psychiatria Danubina

Volumn 22, Issue 3, 2010, Pages 446-449

  Kramberger, Milica Gregorič ^a   Štukovnik, Vita ^a   Čuš, Anja ^a   Repovš, Grega ^b   Tomše, Petra ^a   Meglič, Nuška Pečarič ^a   Garašević, Zdenko ^a   Jensterle, Jože ^c   Pirtošek, Zvezdan ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c Clinical Radiology Institute   (Slovenia)

Author keywords

Cognitive and imaging profile; Parkinson's disease dementia; Perfusion brain SPECT; Treatment

Indexed keywords

TECHNETIUM 99M; ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; CYSTEINE; CYSTEINE ETHYL ESTER TC 99M; TECHNETIUM COMPLEX;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN PERFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; MALE; MOOD DISORDER; MOTOR PERFORMANCE; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANALOGS AND DERIVATIVES; ATROPHY; BRAIN CORTEX; BRAIN MAPPING; DEMENTIA; DIAGNOSTIC USE; DRUG EFFECTS; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PILOT STUDY; PSYCHOMETRY; SCINTISCANNING; STATISTICS; STATISTICS AND NUMERICAL DATA; VASCULARIZATION;

AGED; ANTIPARKINSON AGENTS; ATROPHY; BRAIN MAPPING; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CYSTEINE; DEMENTIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PILOT PROJECTS; PSYCHOMETRICS; STATISTICS AS TOPIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77957703532     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Aarsland et al: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60:387-392. (Pubitemid 36314364)
2. Aarsland et al: Risk of dementia in Parkinson's disease. A community-based prospective study. Neurology 2001; 56: 730-6.
3. Antonini et al: Perfusion ECD/SPECT in the characterisation of cognitive deficits in Parkinson's disease. Neurol Sci 2001;22:45-6.
4. Ballard et al: Fluctuations in attention: Parkinson's disease dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-20.
5. Ballard et al: Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-20.
6. Bissessur et al: rCBF SPECT in Parkinson's disease patients with mental dysfunction. J Neural Transm Suppl 1997; 50:25-30.
7. Ditter SM & Mirra SS: Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987; 37:754-760.
8. Double et al: Regional brain atrophy in idiopathic Parkinson's disease and diffuse lewy body disease. Dementia 1996; 7: 304-13.
9. Ellis et al: Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2000 summer; 12:364-9.
10. Emre et al: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351:2509-18.
11. Emre et al: Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15;22:1689-707.
12. Giladi et al: The effect of treatment with rivastigmin (Exelon) on cognitive functions of patients with dementia and parkinson's disease. Neurology 2001; 56 (suppl 3): A128.
13. Girotti et al: Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51:1498-502.
14. Hietanen M & Teravainen H: Dementia and treatment with L-dopa in Parkinson's disease. Mov Disord 1988;3: 263-70.
15. Huber et al: Magnetic resonance imaging in dementia of Parkinson's disease. J Neurol Neurosurg Psychiatry 1989; 52:1221-7.
16. Laakso et al: Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996;46: 678-81.
17. Litvan et al: Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1991; 54: 25-29.
18. Markus et al: HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. J Neurol Neurosurg Psychiatry 1994; 57:180-5.
19. McKeith et al: Consortium on DLB: Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65:1863-1872.
20. McKeith et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113-1124.
21. McKeith et al: Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999; 53:902-905.
22. McKeith et al: Clozapine in drug induced psychosis in Parkinson's disease:a randomised, placebo controlled study with open follow up J Neurol Neurosurg Psychiatry 2004;75:689-695.
23. McKeith et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-36.
24. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414.
25. Owen AM & Doyon J: The cognitive neuropsychology of Parkinson's disease: a functional neuroimaging perspective. Adv Neurol 1999; 80: 49-56.
26. Pillon et al: Cognitive deficits and dementia in Parkinson's disease. In: Boller F, Cappa S, eds. Handbook of Neuropsychology, 2 edn. Amsterdam: Elsevier Science, 2001: 311-71.
27. Reading et al: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment-preliminary findings from an open trial. Mov Disord 2001; 16:1171-74.
28. Sacks et al: Effects of levodopa in Parkinsonian patients with dementia. Neurology 1972; 22: 516-19.
29. Sawada et al: SPECT findings in Parkinson's disease associated with dementia. J Neurol Neurosurg Psychiatry 1992; 55: 960-3.
30. Scheltens et al: Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal aging: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-72.
31. Spampinato et al: (99mTc) HMPAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1991; 54: 787-92.
32. Stern et al: Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Arch Neurol 1993; 50:1040-1045. (Pubitemid 23301248)
33. Stern et al: Prospective comparative study of the evolution of probable Alzheimer's disease and Parkinson's disease dementia. J Int Neuropsychol Soc 1998; 4:279-284. (Pubitemid 28339749)
34. Tachibana et al: Twelve month follow-up study of regional cerebral blood flow in Parkinson's disease. Dementia 1995; 6:89-93.